Pink SheetEisai is continuing to explore its options on how to enable Australian patients to, access its early Alzheimer’s disease drug, Leqembi (lecanemab), after the Therapeutic Goods Administration again ref
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Start-Up Nosis Partners Its AI Pl
ScripSutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c
Pink SheetIn an unusual decision by NICE, the health technology assessment institute for England is giving Eli Lilly and Eisai a third chance to persuade it to reimburse their respective disease-modifying treat